PI3Kβ
PI3Kβ is a class I PI3K catalytic isoform that produces PIP3, linking receptor inputs to signaling networks that regulate cell growth, survival, and movement[1]. Mechanistically, PI3Kβ uniquely supports synergistic PIP3 formation when GPCR and RTK pathways are coactivated in myeloid cells, whereas p110α, p110β, and p110δ show partial redundancy downstream of M-CSF alone and p110γ acts nonredundantly downstream of C5a alone[1]. In PTEN-deficient breast tumour models, PI3Kβ inactivation reduced STAT3 signaling, increased immune-stimulatory molecules, and promoted anti-tumour immune responses[2]. Compared with related PI3K isoforms, this evidence positions PI3Kβ as a context-specific integrator of coincident receptor signaling and a disease-relevant driver in PTEN-null tumours[1][2]. For experimental applications, the PI3Kβ-selective inhibitor KIN-193 blocked AKT signaling and tumour growth dependent on p110β activation or PTEN loss, while pharmacological PI3Kβ inhibition also synergized with immunotherapy in PTEN-null breast tumour models[3][2].
References:
- [1]. Houslay DM, et al. Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells. Sci Signal. 2016 Aug 16;9(441):ra82. [Content Brief]
- [2]. Bergholz JS, et al. PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature. 2023 May;617(7959):139-146. [Content Brief]
- [3]. Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov. 2012 May;2(5):425-33. [Content Brief]
All Product Categories
-
PI3Kβ Related Products (168)
Related Products (168)
-
LY294002
0 ImagesLY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively. LY294002 also inhibits CK2 with an IC50 of 98 nM. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. LY294002 is an apoptosis activator.
-
Alpelisib
0 ImagesSynonyms: BYL-719Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
-
Pictilisib
0 ImagesSynonyms: GDC-0941Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
-
Idelalisib
0 ImagesSynonyms: CAL-101; GS-1101
-
AZD 6482
0 ImagesSynonyms: KIN-193AZD 6482 (KIN-193) is a potent and selective p110β inhibitor with an IC50 of 0.69 nM.
-
PROTAC PI3Kα degrader-1
0 ImagesCat. No.: HY-174461Purity: 99.21%PROTAC PI3Kα degrader-1 is a PI3Kα PROTAC degrader that recruits CRBN, with a DC50 of 0.08 μM in T47D breast cancer cells. PROTAC PI3Kα degrader-1 inhibits the phosphorylation of AKT at the Ser473 site in cancer cells and exhibits in vivo anticancer efficacy in xenograft models. PROTAC PI3Kα degrader-1 can be used in cancer-related research.
-
PP124
0 ImagesCat. No.: HY-134468CAS No.: 1092788-95-8PP124 is a multi-kinase inhibitor. PP124 inhibits the phosphoinositide 3-kinase (PI3K) catalytic isoforms p110α, p110β, p110δ, and p110γ (IC50 = 4 μM, 7 μM, 0.966 μM, and 1.5 μM), mTOR and DNAPK (IC50 = 0.493 μM and 0.054 μM), as well as the tyrosine kinases Abl, Hck, Src, mutant Src (T/I), VEGFR, EGFR, and EphB4 (IC50 = 0.165 μM, 0.005 μM, 0.017 μM, 0.25 μM, 0.134 μM, 0.085 μM, and 0.17 μM). PP124 can be used for cancer research.
-
Dactolisib
0 ImagesSynonyms: BEZ235; NVP-BEZ235
-
Gedatolisib
0 ImagesSynonyms: PKI-587; PF-05212384
-
Copanlisib
0 ImagesSynonyms: BAY 80-6946Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity.
-
Duvelisib
0 ImagesSynonyms: IPI-145; INK1197Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.
-
Eganelisib
0 ImagesSynonyms: IPI-549
-
Copanlisib dihydrochloride
0 ImagesSynonyms: BAY 80-6946 dihydrochlorideCopanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity.
